--- title: "A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis" nct_id: NCT05197036 overall_status: ACTIVE_NOT_RECRUITING sponsor: Smith & Nephew, Inc. study_type: OBSERVATIONAL primary_condition: Osteoarthritis countries: United States, Australia, Canada, Netherlands, Sweden canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05197036.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05197036" ct_last_update_post_date: 2026-01-30 last_seen_at: "2026-05-12T06:33:35.885Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis **Official Title:** A Multi-Centre Study in Patients Undergoing Total Knee Replacement With Smith+Nephew Porous Total Knee Arthroplasty (TKA) System **NCT ID:** [NCT05197036](https://clinicaltrials.gov/study/NCT05197036) ## Key Facts - **Status:** ACTIVE_NOT_RECRUITING - **Study Type:** OBSERVATIONAL - **Target Enrollment:** 299 - **Lead Sponsor:** Smith & Nephew, Inc. - **Conditions:** Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis - **Start Date:** 2021-12-21 - **Completion Date:** 2033-12-25 - **CT.gov Last Update:** 2026-01-30 ## Brief Summary A clinical trial investigating the safety and effectiveness of Smith and Nephew's FDA-approved Porous Total Knee System, which is used to replace worn away and diseased knee joints. The aim of this study is to show that most patients who receive the Porous Total Knee System have reduced pain, greater mobility and a long-lasting implant post-surgery. ## Detailed Description Patients who need a total knee replacement or have recently had a total knee replacement with the Smith and Nephew Porous Total Knee System will be enrolled into the study. Before surgery X-rays will be collected and questionnaires will be administered which ask the patient about knee pain, activities of daily living, quality of life and how they feel about their knee. The same X-rays and questionnaires will be asked before surgery and then after surgery at various intervals up to 10 years post-surgery. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 80 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: 1. A) Subject needing primary TKA due to degenerative joint disease (primary diagnosis of osteoarthritis), post-traumatic arthritis or inflammatory arthritis. OR B) Subject has undergone primary TKA with Smith+Nephew Porous knee system in past 12 months to repair degenerative joint disease, post- traumatic arthritis or inflammatory arthritis and all the following conditions have been met: * Preoperative KOOS JR and radiographs have been obtained * 6-Month KOOS JR and radiographs have been obtained or these can be collected prospectively in window per schedule of events 2. Subject agrees to consent and to follow the prospective study visit schedule (as defined in the study protocol and informed consent form) by signing the Independent Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form. 3. Subject is willing to attend study follow-up visits for up to five (5) years post-surgery. 4. Subject is able to read, understand, and communicate responses to Patient Reported Outcome assessments. 5. Subject is 18-80 years old (inclusive). Exclusion Criteria: 1. Subject received TKA on the contralateral knee as a revision for a previously failed total or unicondylar knee arthroplasty. 2. Subject has a Body Mass Index (BMI) ≥ 40 at time of surgery. 3. Subject has ipsilateral hip arthritis resulting in flexion contracture. 4. At the time of enrolment, subject has one or more of the following arthroplasties that are not fully healed and well-functioning, as determined by the investigator: Ipsilateral or contralateral primary total hip arthroplasty or hip resurfacing arthroplasty; Contralateral primary total knee or unicondylar knee arthroplasty. 5. Subject has a condition that may interfere with the TKA survival or outcome (e.g. Paget's or Charcot's disease, vascular insufficiency, lupus, muscular atrophy, uncontrolled diabetes, moderate to severe renal insufficiency or neuromuscular disease). 6. Subject has a known allergy to one or more of its components of the study device. 7. Any subject with hardware present in distal femur or proximal tibia. 8. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55. 9. Subject is entered in another drug, biologic, or device study or has been treated with an investigational product in the past 30 days. 10. Subject, in the opinion of the Investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, drug or alcohol abuse. 11. Subject is known to be at risk for lost to follow-up, or failure to return for scheduled visits. 12. Women who are pregnant, nursing, or of child-bearing potential who are not utilizing highly effective birth control measures. 13. Subjects who have participated previously in this clinical trial and who have been withdrawn. ``` ## Arms - **LEGION Porous CR with Hydroxyapatite** — Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR with HA femoral component (min 117 subjects) - **LEGION Porous CR without Hydroxyapatite** — Patients who have already received or a due to receive a Porous Tibia + LEGION Porous CR without HA femoral component (min 117 subjects) ## Interventions - **Total Knee Arthroplasty** (PROCEDURE) — A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses. ## Primary Outcomes - **Implant Survivorship (femoral and/or tibial component) 2 Years Post-Surgery** _(time frame: 2 years post-surgery)_ — Survivorship of the femoral and/or tibial component of the implant is defined as the cumulative proportion of femoral and/or tibial components without a revision. ## Secondary Outcomes - **Patient Reported Outcomes - Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS JR)** _(time frame: Pre-op, 6 weeks, 6 months, 2 years, 3 years, 5 years and 10 years)_ - **Patient Reported Outcomes - Oxford Knee Score (OKS)** _(time frame: Pre-op, 6 weeks, 6 months, 2 years, 3 years, 5 years and 10 years)_ - **Patient Reported Outcomes - Forgotten Joint Score (FJS)** _(time frame: Pre-op, 6 weeks, 6 months, 2 years, 3 years, 5 years and 10 years)_ - **Radiographic Assessment - Implant Position** _(time frame: 6 months, 2 years, 5 years and 10 years)_ - **Radiographic Assessment - Implant Migration** _(time frame: 6 months, 2 years, 5 years and 10 years)_ - **Radiographic Assessment - Progressive Radiolucency** _(time frame: 6 months, 2 years, 5 years and 10 years)_ - **Radiographic Assessment - Implant Loosening** _(time frame: 6 months, 2 years, 5 years and 10 years)_ - **Post-Operation Device Related Re-Interventions Related to Operative Knee** _(time frame: Post-op through study completion, approximately 10 years)_ - **Implant Survival Rate Up to 10 Years Post-Operation** _(time frame: 1 year, 2 years, 5 years and 10 years)_ ## Locations (18) - Emory Orthopaedics and Spine Hospital, Atlanta, Georgia, United States - Massachusetts General Hospital, Boston, Massachusetts, United States - The Core Institute, Novi, Michigan, United States - Syracuse Orthopedic Specialists, East Syracuse, New York, United States - NYU Langone Health Orthopedic Hospital, New York, New York, United States - Columbia University, New York, New York, United States - Duke Health, Morrisville, North Carolina, United States - Oregon Health & Science University, Portland, Oregon, United States - Medical University of South Carolina, Charleston, South Carolina, United States - Erlanger Health, Chattanooga, Tennessee, United States - UTHealth, Houston, Texas, United States - University of Wisconsin, Madison, Wisconsin, United States - St George and Sutherland Centre for Clinical Orthopaedic Research, Sydney, New South Wales, Australia - The Avenue Hospital, Windsor, Victoria, Australia - Concordia Joint Replacement Group, Winnipeg, Manitoba, Canada - Medical Center Leeuwarden, Leeuwarden, Leeuwarden, Netherlands - Sint Maartenskliniek, Ubbergen, Ubbergen,, Netherlands - Umeå University Hospital, Umeå, Umeå, Sweden ## Recent Field Changes (last 30 days) - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.emory orthopaedics and spine hospital|atlanta|georgia|united states` — added _(2026-05-12)_ - `locations.massachusetts general hospital|boston|massachusetts|united states` — added _(2026-05-12)_ - `locations.the core institute|novi|michigan|united states` — added _(2026-05-12)_ - `locations.syracuse orthopedic specialists|east syracuse|new york|united states` — added _(2026-05-12)_ - `locations.nyu langone health orthopedic hospital|new york|new york|united states` — added _(2026-05-12)_ - `locations.columbia university|new york|new york|united states` — added _(2026-05-12)_ - `locations.duke health|morrisville|north carolina|united states` — added _(2026-05-12)_ - `locations.oregon health & science university|portland|oregon|united states` — added _(2026-05-12)_ - `locations.medical university of south carolina|charleston|south carolina|united states` — added _(2026-05-12)_ - `locations.erlanger health|chattanooga|tennessee|united states` — added _(2026-05-12)_ - `locations.uthealth|houston|texas|united states` — added _(2026-05-12)_ - `locations.university of wisconsin|madison|wisconsin|united states` — added _(2026-05-12)_ - `locations.st george and sutherland centre for clinical orthopaedic research|sydney|new south wales|australia` — added _(2026-05-12)_ - `locations.the avenue hospital|windsor|victoria|australia` — added _(2026-05-12)_ - `locations.concordia joint replacement group|winnipeg|manitoba|canada` — added _(2026-05-12)_ - `locations.medical center leeuwarden|leeuwarden|leeuwarden|netherlands` — added _(2026-05-12)_ - `locations.sint maartenskliniek|ubbergen|ubbergen,|netherlands` — added _(2026-05-12)_ - `locations.umeå university hospital|umeå|umeå|sweden` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT05197036.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT05197036* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*